hi to all - showman

[ArchivalUser]

hi to chromosomy stefan 78 doubleblessing antidote....drkhmer...and others ..and silent readers
just getting back to studies full throttle so felt like saying a high to all.

[ArchivalUser]

Hi Showman U post some good questions what is ur source what r u reading from

[ArchivalUser]

Hi SHowman

Keep going buddy...deadlines r coming close

All the Best on your FULLTHROTTLE

[ArchivalUser]

thank yyou chromosomy...i aint applying this year......got low score in step 1 so will apply next year with ck done .....and step 3

[ArchivalUser]

Elevated blood pressure and low-density lipoprotein level have long been recognized as cardiovascular risk factors. A fasting plasma glucose level greater than 126 mg/dL defines diabetes, which is a cardiovascular risk factor. Microalbuminuria has long been recognized as a marker for development of diabetic renal disease but is now also recognized as an important marker of endothelial dysfunction and increased likelihood of developing cardiovascular disease. A C-reactive protein level less than 1.0 mg/dL is considered low risk and has not been shown to be linked to increased risk for cardiovascular disease.

ans is e

[ArchivalUser]

The Adult Treatment Panel Ill defines an optimal LDL cholesterol level as

[ArchivalUser]

The Adult Treatment Panel Ill defines an optimal LDL cholesterol level as less than 100mgldL, and sets this as the goal for patients with coronary heart disease and coronary heart disease risk equivalents. In this patient with known coronary heart disease, his LDL cholesterol is inappropriately elevated at 125 mg/dL. His triglyceride levels and HDL cholesterol are not increased; therefore, the safest and most likely agent to achieve the desired LDL cholesterol goal is either a bile acid sequestrant or ezetimide. A further increase in the statin dosage is not appropriate because he is at the maximal dose and any further increase will be ineffective in achieving the LDL cholesterol goal and will be potentially unsafe. Gemfibrozil is not indicated because it does not significantly lower LDL cholesterol and confers an added risk of development of myositis that sometimes occurs with a statin/fibric acid combination. In some patients, particularly those with elevated triglycerides, gemfibrozil may actually elevate LDL cholesterol.
ans is c

[ArchivalUser]

hi showman

[ArchivalUser]

This patient has mild thyrotoxicosis that probably indicates Graves disease, on the basis of the ophthalmopathy and the diffuse goiter. The laboratory test results are not consistent with normal pregnancy, as she is only about 3 weeks pregnant, the goiter is larger than expected, and ophthalmopathy is present. Because she has Graves disease, treatment with the lowest dose of antithyroid medications that can induce a euthyroid state and alleviate tachycardia is appropriate. Propylthiouracil is the preferred agent because it is less likely than methimazole to cause congenital abnormalities. Methimazole can be used if a patient cannot tolerate propylthiouracil, but at a lower dose than usual (approximately 10 mg once or twice daily). β-Blockers can be used as an adjunctive therapy to alleviate tachycardia and tremor while the patient is still hyperthyroid. They do not treat the underlying hyperthyroidism and would not be appropriate as monotherapy. Once thyroid hormone levels have normalized, β-blocker therapy can be discontinued. Most pregnant women with hyperthyroidism are successfully managed during pregnancy and deliver healthy children. Because of rare cases of placental passage of high levels of thyroid-
ans is b

[ArchivalUser]

stimulating immunoglobulins, the fetus and newborn must be monitored for intrauterine growth retardation and perinatal hyperthyroidism, and thyroid-stimulating immunoglobulins should be measured during the 1 to 2 months of pregnancy